iRhythm Holdings Inc. (NASDAQ: IRTC) presented data at the American College of Cardiology's 2026 Annual Scientific Sessions showing high rates of clinically actionable arrhythmias in patients with cardiovascular-kidney-metabolic conditions using its Zio ambulatory ECG monitoring service.

The company analyzed data from its clinical warehouse linked to commercial and government insurance claims. In a study of 657,147 patients who received 14-day continuous monitoring, clinically actionable arrhythmias affected 48% of patients with chronic kidney disease and 47% of patients with both diabetes and chronic kidney disease, compared to 39% with diabetes alone and 35% with neither condition.

A separate analysis of 162,531 patients found that atrial fibrillation detection increased with body weight, rising from 4.5% in normal/underweight patients to 6.5% in patients with severe obesity. After adjusting for age, sex and comorbidities, patients with severe obesity had nearly three times higher odds of atrial fibrillation detection.

Chief Medical Officer Mintu Turakhia delivered the 57th Annual Louis F. Bishop Keynote on scaling artificial intelligence in cardiology. "The primary barrier to impact is no longer technical development or model performance — most AI across diagnostics, clinical decision support, and other domains work well," Turakhia said.

iRhythm launched iRhythm Academy, an education platform offering courses, webinars and learning modules for healthcare professionals focused on ambulatory cardiac monitoring. The company also announced an upcoming Spanish-language update to its MyZio mobile app for patients.

The data builds on iRhythm's clinical evidence program, which encompasses more than 135 research manuscripts and insights from over 3 billion hours of heartbeat data since the company's inception.